EUVIMEDEUVIMED entdecken
Open Access

Clinical Management of Synchronous and Metachronous Renal Lesions in Patients With Oncocytoma Treated With Nephrectomy: A 30-Year Single-Center Experience

Lennert Eismann, Stephen W Reese, Mark T Dawidek, Lina Posada Calderon, Andreas Aulitzky, Katiana Vazquez-Rivera, Jonathan A Coleman, Christian G Stief, Ed Reznik, Paul Russo, Abraham Ari Hakimi

Clinical Genitourinary Cancer · 2026-02 · 24 (1) · 102463

DOI: 10.1016/j.clgc.2025.102463 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Genitourinary Cancer, 2026-02. Verfasst von Lennert Eismann und 10 weiteren Autor:innen. Beteiligte Einrichtung: Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Urology, Ludwig-Maximilians University, M…. Hauptthemen laut MEDLINE: Adenoma, Oxyphilic, Kidney Neoplasms, Nephrectomy, Neoplasms, Second Primary. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, German Research Foundation, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The natural history of renal oncocytoma (RO) following surgical resection remains unclear. We examined a cohort of post-nephrectomy patients with RO, focusing on the management of synchronous and metachronous tumors and their clinical course under surveillance. METHODS: This retrospective, single-institution study analyzed patients from 1990 to 2020 with at least 24 months of follow-up. Patient characteristics and management of synchronous and metachronous tumors were recorded. Cox regression identified risk factors for metachronous tumors, while Kaplan-Meier and log-rank tests assessed metachronous-free survival (MFS). RESULTS: Among 328 patients (median follow-up: 109 months), 19% (n = 63) had synchronous renal tumors on preoperative imaging. Of these, 27 underwent additional procedures, revealing renal cell carcinoma (RCC)/cortical neoplasm (n = 7), benign lesions (n = 5), or secondary RO (n = 13). Two specimens were unavailable. Metachronous renal lesions developed in 8.5% (n = 28), with 18 undergoing active surveillance. Among 8 patients undergoing biopsy or surgery, 3 had RCC/cortical neoplasm, 4 had RO, and 1 specimen was inconclusive. 5-year MFS were 98.8% in patients with a single lesion at diagnosis and 88% for patients with presence of synchronous renal lesions (P = .004). Higher BMI (HR 1.09, CI 1.01-1.17, P = .026) and synchronous lesions at diagnosis (HR 2.67, CI 1.16-6.14, P = .021) were significant risk factors for metachronous tumors. CONCLUSION: Patients with RO have a very low risk of harboring RCC in synchronous or metachronous lesions, supporting active surveillance as a safe strategy. However, those with synchronous kidney tumors at diagnosis face an increased risk of metachronous disease and may require closer monitoring.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenoma, OxyphilicKidney NeoplasmsNephrectomyNeoplasms, Second PrimaryNeoplasms, Multiple PrimaryCarcinoma, Renal CellHumansMaleFemaleMiddle AgedRetrospective StudiesAgedAdultFollow-Up StudiesRisk FactorsWatchful Waiting

Stichwörter der Autor:innen

Active surveillanceClinical managementRecurrenceRenal oncocytomaSmall renal mass

Autor:innen und Institutionen

  • Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Urology, Ludwig-Maximilians University, Munich, Germany.
  • Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Urology, Ludwig-Maximilians University, Munich, Germany.
  • Computational Oncology Service, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: hakimia@mskcc.org.

Förderung

  • NCI NIH HHS
  • German Research Foundation
  • National Institutes of Health
  • Sidney Kimmel Center for Prostate and Urologic Cancers
  • National Cancer Institute

Zitieren

APA

Eismann, L., Reese, S. W., Dawidek, M. T., Calderon, L. P., Aulitzky, A., Vazquez-Rivera, K., Coleman, J. A., Stief, C. G., Reznik, E., Russo, P., & Hakimi, A. A. (2026). Clinical Management of Synchronous and Metachronous Renal Lesions in Patients With Oncocytoma Treated With Nephrectomy: A 30-Year Single-Center Experience. Clinical Genitourinary Cancer, 24(1), 102463. https://doi.org/10.1016/j.clgc.2025.102463

Vancouver

Eismann L, Reese SW, Dawidek MT, Calderon LP, Aulitzky A, Vazquez-Rivera K, et al. Clinical Management of Synchronous and Metachronous Renal Lesions in Patients With Oncocytoma Treated With Nephrectomy: A 30-Year Single-Center Experience. Clinical Genitourinary Cancer. 2026;24(1):102463. doi:10.1016/j.clgc.2025.102463

BibTeX
@article{Eismann2026,
  author = {Eismann, Lennert and Reese, Stephen W and Dawidek, Mark T and Calderon, Lina Posada and Aulitzky, Andreas and Vazquez-Rivera, Katiana and Coleman, Jonathan A and Stief, Christian G and Reznik, Ed and Russo, Paul and Hakimi, Abraham Ari},
  title = {Clinical Management of Synchronous and Metachronous Renal Lesions in Patients With Oncocytoma Treated With Nephrectomy: A 30-Year Single-Center Experience},
  journal = {Clinical Genitourinary Cancer},
  year = {2026},
  volume = {24},
  number = {1},
  pages = {102463},
  doi = {10.1016/j.clgc.2025.102463}
}
Kostenlos starten →